Sandoz has revealed that it is considering launching its Tyruko (natalizumab-sztn) biosimilar rival to Biogen’s Tysabri “at risk” in the US, while litigation with the originator continues.
Buoyed by a court decision earlier this year that refused to grant originator Biogen an injunction to keep Tyruko off the market (see sidebar), Sandoz disclosed as it reported nine-month results that US and European launches of the Polpharma